Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression.

Massion PP, Taflan PM, Shyr Y, Rahman SM, Yildiz P, Shakthour B, Edgerton ME, Ninan M, Andersen JJ, Gonzalez AL.

Am J Respir Crit Care Med. 2004 Nov 15;170(10):1088-94. Epub 2004 Aug 18.

PMID:
15317667
2.

A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.

Korkolopoulou P, Levidou G, Trigka EA, Prekete N, Karlou M, Thymara I, Sakellariou S, Fragkou P, Isaiadis D, Pavlopoulos P, Patsouris E, Saetta AA.

BJU Int. 2012 Dec;110(11 Pt C):E1237-48. doi: 10.1111/j.1464-410X.2012.11569.x. Epub 2012 Oct 29.

3.

PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma.

Kozaki K, Imoto I, Pimkhaokham A, Hasegawa S, Tsuda H, Omura K, Inazawa J.

Cancer Sci. 2006 Dec;97(12):1351-8.

4.

Significance of p63 amplification and overexpression in lung cancer development and prognosis.

Massion PP, Taflan PM, Jamshedur Rahman SM, Yildiz P, Shyr Y, Edgerton ME, Westfall MD, Roberts JR, Pietenpol JA, Carbone DP, Gonzalez AL.

Cancer Res. 2003 Nov 1;63(21):7113-21.

6.

Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer.

Woenckhaus J, Steger K, Sturm K, Münstedt K, Franke FE, Fenic I.

Virchows Arch. 2007 Apr;450(4):387-95. Epub 2007 Feb 15.

PMID:
17377809
7.

HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization.

Tan D, Deeb G, Wang J, Slocum HK, Winston J, Wiseman S, Beck A, Sait S, Anderson T, Nwogu C, Ramnath N, Loewen G.

Diagn Mol Pathol. 2003 Dec;12(4):201-11.

PMID:
14639106
8.

Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.

Fenic I, Steger K, Gruber C, Arens C, Woenckhaus J.

Oncol Rep. 2007 Jul;18(1):253-9.

PMID:
17549376
9.

Molecular alterations in AKT and its protein activation in human lung carcinomas.

Dobashi Y, Kimura M, Matsubara H, Endo S, Inazawa J, Ooi A.

Hum Pathol. 2012 Dec;43(12):2229-40. doi: 10.1016/j.humpath.2012.03.015. Epub 2012 Jun 28.

PMID:
22748472
10.

Phosphatidylinositol 3-kinase could be a promising target in lung cancer therapy.

Wang H, Wu H, Cai K, Ju Q, Wang W.

J BUON. 2012 Oct-Dec;17(4):729-34.

PMID:
23335533
11.

Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer.

Aleskandarany MA, Rakha EA, Ahmed MA, Powe DG, Ellis IO, Green AR.

Breast Cancer Res Treat. 2011 Jun;127(2):407-16. doi: 10.1007/s10549-010-1012-y. Epub 2010 Jul 9.

PMID:
20617378
12.

Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions.

Balsara BR, Pei J, Mitsuuchi Y, Page R, Klein-Szanto A, Wang H, Unger M, Testa JR.

Carcinogenesis. 2004 Nov;25(11):2053-9. Epub 2004 Jul 7.

PMID:
15240509
13.

High prevalence of fatty acid synthase expression in colorectal cancers in Middle Eastern patients and its potential role as a therapeutic target.

Uddin S, Hussain AR, Ahmed M, Abubaker J, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Bavi P, Al-Kuraya KS.

Am J Gastroenterol. 2009 Jul;104(7):1790-801. doi: 10.1038/ajg.2009.230. Epub 2009 Jun 2.

PMID:
19491830
14.

PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma.

Abe A, Minaguchi T, Ochi H, Onuki M, Okada S, Matsumoto K, Satoh T, Oki A, Yoshikawa H.

Hum Pathol. 2013 Feb;44(2):199-207. doi: 10.1016/j.humpath.2012.05.005. Epub 2012 Sep 3.

PMID:
22955107
15.

PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis.

Aleskandarany MA, Rakha EA, Ahmed MA, Powe DG, Paish EC, Macmillan RD, Ellis IO, Green AR.

Breast Cancer Res Treat. 2010 Jul;122(1):45-53. doi: 10.1007/s10549-009-0508-9. Epub 2009 Aug 22.

PMID:
19701705
16.

Frequent PIK3CA gene amplification and its clinical significance in colorectal cancer.

Jehan Z, Bavi P, Sultana M, Abubaker J, Bu R, Hussain A, Alsbeih G, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Uddin S, Al-Kuraya KS.

J Pathol. 2009 Nov;219(3):337-46. doi: 10.1002/path.2601.

PMID:
19697359
17.

Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.

Catasus L, Gallardo A, Cuatrecasas M, Prat J.

Mod Pathol. 2009 Apr;22(4):522-9. doi: 10.1038/modpathol.2009.5. Epub 2009 Feb 20.

18.

HER-2, EGFR, COX-2 expression status correlated to microvessel density and survival in resected non-small cell lung cancer.

Brattström D, Wester K, Bergqvist M, Hesselius P, Malmström PU, Nordgren H, Wagenius G, Brodin O.

Acta Oncol. 2004;43(1):80-6.

PMID:
15068324
19.

Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.

Sun CH, Chang YH, Pan CC.

Histopathology. 2011 Jun;58(7):1054-63. doi: 10.1111/j.1365-2559.2011.03856.x.

PMID:
21707707
20.

Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma.

Bolli M, Kocher T, Adamina M, Guller U, Dalquen P, Haas P, Mirlacher M, Gambazzi F, Harder F, Heberer M, Sauter G, Spagnoli GC.

Ann Surg. 2002 Dec;236(6):785-93; discussion 793.

Supplemental Content

Support Center